This drug is currently the centre of attraction for development as an anti-cancer agent for many different human cancers, and has demonstrated anInhibition of prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signalling in lung cancer cells and human lung tumour-associated endothelial cells53. Here, MAP2K7 is linked to cancer.